The Phenobarbital Market Size is valued at USD 1.48 Bn in 2022 and is predicted to reach USD 2.20 Bn by the year 2031 at a 4.6% CAGR during the forecast period for 2023-2031.
Phenobarbital acts as a central nervous system depressant. It enhances the activity of a neurotransmitter called gamma-aminobutyric acid (GABA), which inhibits brain activity. This results in a calming effect on the brain, making it useful for conditions involving seizures and anxiety. High effectiveness in the long-term management of seizures and other neurological conditions is anticipated to drive market growth during the forecast period. Furthermore, good patient compliance, as well as a large selection and simple management by healthcare practitioners, boosts the market expansion. Raising awareness among healthcare professionals is expected to propel the market growth.
High chances of addiction and overdose are anticipated to hinder market growth. Drowsiness and vertigo are potential adverse effects which are hampering the market expansion. Moreover, strict government regulations will hamper the market growth in the coming years. The possibility of reaching emerging markets and increasing levels of field research and development creates opportunities in the market during the forecast period.
Market Segmentation:
The phenobarbital market is segmented on the basis of indication, dosage form and distribution channel. As per the indication, the market is segmented as epilepsy and neonatal seizures. By dosage form, the market is segmented into tablets, injectables, and formulations. On the basis of distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies.
Based On Indication, The Epilepsy Segment Is Accounted As A Major Contributor To The Phenobarbital Market
The epilepsy category is expected to hold a major share in the global phenobarbital market in 2022 due to the high use of phenobarbital in status epilepticus treatment and anti-seizure management in epileptic patients, which is anticipated to drive the market growth. Phenobarbital prolongs the duration that chloride channels are open, which causes the central nervous system to become depressed.
By interacting with GABA-A receptor subunits, this effect takes place. The chloride ion gates open and remain open when phenobarbital binds to these receptors, allowing a constant flow of these ions into neuronal cells. The cell membrane becomes hyperpolarized as a result, raising the action potential threshold. This medication works well to treat seizures because of its increased action potential.
On The Basis Of Dosage Form, The Tablets Segment Witnessed Growth At A Rapid Rate
The tablet segment is expected to grow at a rapid rate in the global phenobarbital market owing to easier to handle and comfortable administration than another dosage forms such as injectables. Furthermore, the ease of carrying tablet dosage forms for geriatric patients is another advantage of tablet dosage forms, which is anticipated to drive the market growth.
In The Region, The North American Phenobarbital Market Holds A Significant Revenue Share
The North American phenobarbital market is expected to register the maximum market share in terms of revenue in the near future. This can be attributed to the greater incidence of alternative anti-convulsant medication and well-developed healthcare infrastructure. Increasing technological developments are major factors anticipated to boost the market advancement during the forecast period. High efficacy and affordability of phenobarbital are some of the factors impelling the market growth in the coming years.
Phenobarbital Market Report Scope:
|
Report Attribute |
Specifications |
|
Market size value in 2022 |
USD 1.48 Bn |
|
Revenue forecast in 2031 |
USD 2.20 Bn |
|
Growth rate CAGR |
CAGR of 4.6% from 2023 to 2031 |
|
Quantitative units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
By Indication, Distribution Channel, Dosage Forms |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Sanofi, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Zydus Cadila, Lannett Company, Inc., Strides Pharma Science Limited, Cipla Ltd., Lupin Limited, Aurobindo Pharma Limited, Torrent Pharmaceuticals Ltd., Reddy's Laboratories Ltd. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
